TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35021015
Drug: Linguistic-phonological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linguistic-phonological intervention to eliminate non-oral CSCs
Study: 36302173
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg)
Study: 32517192
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide)
Study: 33184437
Drug: Dietary probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary probiotic supplement of four viable strains of Lactobacillus twice-daily for 14 days
Study: 35407595
Drug: Negative pulsed-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pulsed-pressure myofascial vacuum therapy (VT)
Study: 35407595
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program (PTP) based only on core therapeutic exercise
Study: 32763548
Drug: Quetiapine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (100 mg)
Study: 34150674
Drug: Oral liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liposomal glutathione supplementation (L-GSH) for 3 months
Study: 38498141
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg
Study: 35833298
Drug: 7+3 induction
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7+3 induction chemotherapy
Study: 39575611
Drug: Clonidine therapy
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine therapy
Study: 34228086
Drug: Antibiotic initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibiotic initiation letter (n = 1500)
Study: 34228086
Drug: Antibiotic duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic duration letter (n = 1500)
Study: 35820743
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg guanabenz acetate
Study: 35820743
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg guanabenz acetate
Study: 32755065
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (NPA group)
Study: 33602313
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injections
Study: 32375688
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of neoadjuvant chemotherapy (NAC)
Study: 32375688
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of neoadjuvant chemotherapy (NAC)
Study: 32375688
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups will undergo interval debulking surgery (IDS) and then receive 3 or 4 cycles of adjuvant chemotherapy for a total of 6 cycles.
Study: 33263788
Drug: Fasting appetite-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting appetite-related hormones
Study: 33263788
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in leptin and insulin levels
Study: 34913497
Drug: TMFI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMFI + Steroid
Study: 32762115
Drug: Irbesartan 100
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 100 mg/amlodipine 10 mg (Group 1)
Study: 32762115
Drug: Indapamide 1
Normalized name: indapamide 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1 mg in addition to ARBs plus amlodipine 5 mg (Group 2)
Study: 36137765
Drug: Pre-transfusion haemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-transfusion haemoglobin <75g/L
Study: 33350863
Drug: Lebrikizumab (IL-13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab (IL-13 inhibitor)
Study: 33350863
Drug: Tralokinumab (IL-13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (IL-13 monoclonal antibody)
Study: 35325728
Drug: Cerebellar anodal
Normalized name: Sus scrofa cerebellum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebellar anodal transcranial direct current stimulation (a‐tDCS) concurrent with postural training (cerebellar a‐CSC‐PT)
Study: 32659768
Drug: Ostrich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ostrich oil massage (1 mL on pruritus area for 10 min each night for 1 month)
Study: 36897544
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg
Study: 33355910
Drug: Tegoprazan 100
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 100 mg
Study: 37691796
Drug: Attachment-based compassion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based compassion therapy (ABCT)
Study: 35389054
Drug: Skin-adhesive low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-adhesive low-level light therapy (LLLT) device (Color DNA-WSF) applied three times daily for 12 weeks
Study: 35389054
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham device applied three times daily for 12 weeks
Study: 35389054
Drug: Skin-adhesive low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-adhesive low-level light therapy (LLLT) device (Color DNA-WSF)
Study: 32872022
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of chemotherapy
Study: 32073564
Drug: Intranasal Glycyrrhetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Glycyrrhetic acid (GlyAc)
Study: 34758065
Drug: Antidepressant response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antidepressant response
Study: 611925637
Drug: beta-alanine supplementation
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-alanine supplementation (3 g/day for 7 days, then 6 g/day for 23 days)
Study: 36169441
Drug: Beifushu eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beifushu eye drops (recombinant bovine basic fibroblast growth factor) 6 times daily for 1 week
Study: 36169441
Drug: 0.1% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sodium hyaluronate eye drops (artificial tears) 6 times daily for 1 week
Study: 32816096
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (individual guidance on disease management, lifestyle advice, blinded regulation of medication)
Study: 35490877
Drug: Emotional memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotional memory reactivation electroconvulsive therapy (EMR-ECT)
Study: 35490877
Drug: Control memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control memory reactivation electroconvulsive therapy (CMR-ECT)
Study: 34243746
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care provided at discharge from treatment
Study: 33249492
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioral therapy for insomnia (dCBT‐I)
Study: 32382745
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone (Axiron)
Study: 32354432
Drug: Clear aligner
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear aligner therapy (CA)
Study: 32354432
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance therapy (FA)
Study: 36007218
Drug: Anti-EGFR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR therapy
Study: 33660142
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy
Study: 33594388
Drug: rVSV-EBOV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV-EBOV vaccine
Study: 32391919
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (LAmB) 3.0 mg/kg/d
Study: 32391919
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole (ivITCZ) induction: 400 mg/d, maintenance: 200 mg/d
Study: 33486058
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg administered within 90 minutes of surgery)
Study: 33740360
Drug: Intra- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra- and post-operative opioid administration
Study: 35608484
Drug: Liberal approach
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal approach to glucose control (intravenous insulin commenced at blood glucose >252 mg/dL, titrated to 180-252 mg/dL)
Study: 35608484
Drug: Comparator approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator approach to glucose control (insulin commenced at blood glucose >180 mg/dL, titrated to 108-180 mg/dL)
Study: 35115706
Drug: H2HA-Ferritin 20-μg
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2HA-Ferritin 20-μg dose (n=5)
Study: 35115706
Drug: H2HA-Ferritin 60-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2HA-Ferritin 60-μg dose in homologous prime-boost regimen (n=25)
Study: 35115706
Drug: H2HA-Ferritin 60-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2HA-Ferritin 60-μg dose in heterologous prime-boost regimen (n=20)
Study: 35115706
Drug: H2 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 DNA vaccine (control group, n=5)
Study: 35115706
Drug: H2HA-Ferritin vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2HA-Ferritin vaccine
Study: 39507456
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid therapy
Study: 33470281
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection alone
Study: 35100493
Drug: LC hair
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC hair essence serum (1 ml diluted with 0.5 ml of 0.9% normal saline, injected once weekly for 8 weeks)
Study: 32007239
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at a rate of 0.4 μg kg‐1 h‐1 for 24 h
Study: 35568917
Drug: True APP
Approvals — FDA: no, EMA: no, PMDA: no
Description: True APP therapy
Study: 35568917
Drug: Sham point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham point stimulation therapy
Study: 35726852
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group with beetroot juice supplement (EX&BRJS)
Study: 35726852
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice supplement group (BRJS)
Study: 32989714
Drug: Generic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drugs
Study: 32167605
Drug: 14-day reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day reverse hybrid therapy (dexlansoprazole 60 mg o.d. plus amoxicillin 1 g b.d. for 14 days, and clarithromycin 500 mg plus metronidazole 500 mg b.d. for initial 7 days)
Study: 32167605
Drug: 14-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day concomitant therapy (dexlansoprazole 60 mg o.d. plus amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg b.d. for 14 days)
Study: 32167605
Drug: 14-day reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day reverse hybrid therapy
Study: 32167605
Drug: 14-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day concomitant therapy
Study: 33840495
Drug: Relaxation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation group (listened to a prerecorded relaxation breathing session before and during the injection)
Study: 33840495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received the injection without a relaxation session)
Study: 35486013
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (ioratadine tablets, 1 tablet daily for 10 days, 3 sessions)
Study: 32014686
Drug: High-dose systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose systemic interferon-α2b (HDI) following dendritic cell (DC) vaccination
Study: 32014686
Drug: High-dose systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose systemic interferon-α2b (HDI)
Study: 32028480
Drug: Electroabrasion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroabrasion treatment on half of the wound
Study: 32028480
Drug: Electroabrasion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroabrasion treatment
Study: 32022863
Drug: Once-weekly somapacitan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly somapacitan
Study: 37697811
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy (MMT)
Study: 34456060
Drug: Intranasal varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal varenicline 0.12 mg in OC‐01 nasal spray
Study: 34456060
Drug: Oral varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral varenicline 1 mg
Study: 36380332
Drug: Normothermia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia with early treatment of fever (body temperature, ≥37.8 °C)
Study: 33386046
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (12 sessions, 40 minutes, 3 times a week for 4 weeks)
Study: 34351508
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) in a tumescent solution prior to liposuction
Study: 35733624
Drug: TMP‐4 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐4 cream
Study: 32847403
Drug: MaxiPost (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxiPost (0.05 mg/min BKCa channel opener)
Study: 35925430
Drug: NOL-guided intraoperative
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOL-guided intraoperative administration of fentanyl
Study: 34987033
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (50 mg/kg body weight per dose, two times per day for 5 days)
Study: 33877707
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (1800 IU/day)
Study: 33877707
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 (700 IU/day)
Study: 32711853
Drug: Sucralose consumption
Normalized name: Sucralose
DrugBank: Sucralose (DB15049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose consumption at 15% of the acceptable daily intake using commercial sachets added to food
Study: 37813418
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group
Study: 34996629
Drug: Daily teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily teriparatide (TPTD) injections (20 μg)
Study: 34996629
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide (TPTD) injections (56.5 μg)
Study: 34996629
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative therapy (non-TPTD group)
Study: 34668331
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 15 mg/kg intravenous TXA postoperatively at 2 and 24 hours after closing the incision (group A)
Study: 34668331
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 15 mg/kg intravenous TXA 2 hours postoperatively (group B)
Study: 32302665
Drug: lixisenatide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lixisenatide + basal insulin
Study: 32302665
Drug: sulphonylurea +
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphonylurea + basal insulin
Study: 34142743
Drug: Once-weekly exenatide-LAR
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly exenatide-LAR injection with weekly nurse review for 20 weeks
Study: 34142743
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with weekly nurse review for 20 weeks
Study: 35189925
Drug: UC-MSCs (106
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSCs (106 UC-MSCs/kg, three intravenous infusions over 5 days)
Study: 35189925
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl, three intravenous infusions over 5 days)
Study: 34656412
Drug: HIPEC (hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (hyperthermic intraperitoneal chemotherapy)
Study: 37474729
Drug: Cyclosporine treatment
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine treatment
Study: 34452971
Drug: Bisoprolol once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol once daily (1.25-5 mg, dependent on tolerated dose)
Study: 35473344
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) decoction
Study: 35473344
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine treatment
Study: 32268897
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (up to 3 g/day) for up to 2 years
Study: 32628436
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about tetanus vaccine
Study: 36058618
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation therapy (RT) with internal mammary nodal irradiation
Study: 36058618
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation therapy (RT) without internal mammary nodal irradiation
Study: 34746745
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of Depo-Provera
Study: 34746745
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of Depo-Provera
Study: 36274108
Drug: Heparin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin during the procedure
Study: 36163843
Drug: Oral-AZA 300mg
Normalized name: Aza-epothilone B
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-AZA 300mg once-daily for 14 days/28-day cycle
Study: 36163843
Drug: Oral-AZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-AZA
Study: 34178834
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU intramuscularly monthly for six months
Study: 34178834
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (0.25 mL) monthly for six months (Control)
Study: 34178834
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 treatment group after 6 months of stopping treatment
Study: 33884938
Drug: Conventional compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional compression therapy (Group B)
Study: 34116144
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment of physician's choice (TPC)
Study: 39060905
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 or 10 mg twice daily
Study: 32375655
Drug: Co-occurrence of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-occurrence of axial pain and a prescription for nonsteroidal anti-inflammatory drug within 30 days
Study: 35917265
Drug: Intradermal Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Botulinum toxin A injection
Study: 35917265
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% glycopyrrolate
Study: 32871985
Drug: Basic acupuncture
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic acupuncture and the herbal formulation dangui yinzi
Study: 33108521
Drug: Salmon (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (750 g/week)
Study: 32450908
Drug: Bujing Yishi
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bujing Yishi tablets (BJYSP)